Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Developmental Disorder Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Satisfaction Rates Among Parents of Children With Autism in the ED

NCT02675933
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Questionnaire
Behavioral
Lead sponsor
Seton Healthcare Family
Other
Eligibility
2 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder

NCT02985749
View directory record Official record
Conditions
Autism Spectrum Disorder, Pervasive Developmental Disorder, ASD, PDD
Interventions
Intranasal Oxytocin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia

NCT01839240
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
azacitidine, cytarabine, mitoxantrone hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Sep 7, 2026, 2:34 PM EDT
Active, not recruiting No phase listed Observational

Patient and Healthcare Professional Views on Genetic/Genomic Information and Testing

NCT04733274
View directory record Official record
Conditions
Hypogonadism, Hypogonadotropic, Kallmann Syndrome
Interventions
Not listed
Lead sponsor
Boston College
Other
Eligibility
18 Years to 70 Years
Enrollment
227 participants
Timeline
2018 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exploring Predictors of Response to a Peer-Mediated Intervention for Preschoolers With ASD

NCT05277103
View directory record Official record
Conditions
Autism Spectrum Disorder, Nonverbal Communication
Interventions
Exploring predictors of response to a peer-mediated communication intervention for minimally verbal preschoolers with ASD
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
3 Years to 6 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Phase 2 Interventional

The Effect of Prior Learning on Word Learning

NCT05921188
View directory record Official record
Conditions
Language Development Disorders
Interventions
VAULT Phase 4
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
2 Years to 4 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 7, 2026, 2:34 PM EDT
Completed No phase listed Observational

A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

NCT03955913
View directory record Official record
Conditions
Urothelial Cancer, Receptors, Fibroblast Growth Factor
Interventions
Archival Tumor Tissue Sample
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
3,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 7, 2026, 2:34 PM EDT
Completed No phase listed Observational

Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing

NCT01546324
View directory record Official record
Conditions
Pregnancy Following IVF With PGS/PGD
Interventions
Blood draw
Procedure
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2013 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD)

NCT04644003
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
STP1, Placebo
Drug
Lead sponsor
Stalicla SA
Industry
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 7, 2026, 2:34 PM EDT
Completed No phase listed Observational

Cause, Development, and Progression of Stiff-Person Syndrome

NCT00030940
View directory record Official record
Conditions
Stiff-Person Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 7, 2026, 2:34 PM EDT
Active, not recruiting Not applicable Interventional

Developmental Intervention for Hospitalized Newborns With Congenital Heart Disease

NCT05885113
View directory record Official record
Conditions
Cardiology, Infant Development, Development Delay
Interventions
NIDCAP Developmental Care
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 4 Months
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Growth Hormone and Chromosome 18q- and Abnormal Growth

NCT00134420
View directory record Official record
Conditions
Loss of Chromosome 18q, Growth Hormone Deficiency
Interventions
Nutropin AQ, Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, Neuropsychological Testing
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream

NCT01853423
View directory record Official record
Conditions
Facial Angiofibroma
Interventions
Rapamune
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
3 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Not applicable Interventional Results available

Transcranial Photobiomodulation for Reducing Autism Symptoms in Children - Open Label Study (TPBMASDOL)

NCT06359080
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Cognilum TM: Light Treatment Condition
Device
Lead sponsor
JelikaLite LLC
Industry
Eligibility
2 Years to 7 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 7, 2026, 2:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

NCT07681596
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
AZD4045, Daratumumab, Aldesleukin
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
Duarte, California • Denver, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 7, 2026, 2:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transcranial Direct Current Stimulation (tDCS) and Cognitive Processing

NCT01602263
View directory record Official record
Conditions
Aphasia, Autism, Schizophrenia
Interventions
Transcranial Direct Current Stimulation (tDCS)
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 79 Years
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 7, 2026, 2:34 PM EDT
Withdrawn Phase 3 Interventional

A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)

NCT01157949
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Thymoglobulin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Myocardial Perfusion Imaging Galmydar Rest/Stress

NCT05625490
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ga-68 Galmydar, 13N-ammonia
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 7, 2026, 2:34 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Childhood Outcomes of Preterm Brain Abnormalities

NCT03410810
View directory record Official record
Conditions
Premature Birth, Neurodevelopmental Disorders, Brain Development Abnormality, Brain Lesion
Interventions
MRI, Neurodevelopmental/Neuropsychological Assessment
Diagnostic Test
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 8 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Sep 7, 2026, 2:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Pilot Factorial Trial of an Integrated Lifestyle Intervention

NCT06116435
View directory record Official record
Conditions
Physical Inactivity, Overweight and Obesity
Interventions
Prevent T2, Move group-based classes, Fitness Membership, Mental Imagery, Move 1:1 Support
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 7, 2026, 2:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

NCT06063850
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
AAV9-hSyn1-miGRIK2
Genetic
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 7, 2026, 2:34 PM EDT
Terminated Phase 4 Interventional Results available

Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size

NCT03043274
View directory record Official record
Conditions
STEMI - ST Elevation Myocardial Infarction
Interventions
Cangrelor
Drug
Lead sponsor
Khaled Ziada, MD
Other
Eligibility
18 Years to 99 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 7, 2026, 2:34 PM EDT
Terminated Phase 4 Interventional Results available

Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation

NCT03247413
View directory record Official record
Conditions
Neuritis, Radiofrequency Ablation
Interventions
Dexamethasone 4 mg/ml, Normal saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

NCT00131989
View directory record Official record
Conditions
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia
Interventions
sorafenib tosylate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Sep 7, 2026, 2:34 PM EDT